BR112018015754A2 - anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1 - Google Patents

anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1

Info

Publication number
BR112018015754A2
BR112018015754A2 BR112018015754A BR112018015754A BR112018015754A2 BR 112018015754 A2 BR112018015754 A2 BR 112018015754A2 BR 112018015754 A BR112018015754 A BR 112018015754A BR 112018015754 A BR112018015754 A BR 112018015754A BR 112018015754 A2 BR112018015754 A2 BR 112018015754A2
Authority
BR
Brazil
Prior art keywords
diabetes
prevention
compositions
treatment
methods
Prior art date
Application number
BR112018015754A
Other languages
English (en)
Portuguese (pt)
Inventor
Paxson Bethany
Hsia Elizabeth
Leu Jocelyn
Hedrick Joseph
Rigby Mark
Imm Paul
Zoka Ramineh
Zheng Songmao
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112018015754A2 publication Critical patent/BR112018015754A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A61M5/003—Kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31566—Means improving security or handling thereof
    • A61M5/31573—Accuracy improving means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31591—Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BR112018015754A 2016-02-05 2017-02-02 anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1 BR112018015754A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291673P 2016-02-05 2016-02-05
PCT/US2017/016175 WO2017136524A2 (en) 2016-02-05 2017-02-02 Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Publications (1)

Publication Number Publication Date
BR112018015754A2 true BR112018015754A2 (pt) 2019-01-29

Family

ID=59500155

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015754A BR112018015754A2 (pt) 2016-02-05 2017-02-02 anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1

Country Status (11)

Country Link
US (3) US10465003B2 (enExample)
EP (1) EP3411504A4 (enExample)
JP (1) JP2019509988A (enExample)
KR (1) KR20180105711A (enExample)
CN (1) CN109072303A (enExample)
AU (1) AU2017215317A1 (enExample)
BR (1) BR112018015754A2 (enExample)
CA (1) CA3012465A1 (enExample)
MA (1) MA43982A (enExample)
MX (1) MX2018009498A (enExample)
WO (1) WO2017136524A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US12018075B2 (en) 2018-04-20 2024-06-25 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-TNF antibody compositions
AU2020208828A1 (en) * 2019-01-15 2021-08-05 Janssen Biotech, Inc. Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
US20220064278A1 (en) * 2019-01-23 2022-03-03 Janssen Biotech, Inc. Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
CA3133383A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
MA55282A (fr) * 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
CA3133388A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2021028752A1 (en) * 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021075535A1 (ja) * 2019-10-18 2021-04-22 国立大学法人滋賀医科大学 異常幹細胞を標的とする糖尿病治療
US20220403032A1 (en) * 2019-10-18 2022-12-22 BioZipcode, Inc. Therapy for diabetes using stem cell migration agent
WO2021164717A1 (zh) * 2020-02-20 2021-08-26 百奥泰生物制药股份有限公司 抗TNF-α的抗体制剂及其制备方法和用途
CN115461365A (zh) * 2020-04-27 2022-12-09 詹森生物科技公司 用于治疗幼年特发性关节炎的物质和方法
EP4596046A3 (en) 2020-05-21 2025-10-22 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung
WO2022171685A1 (en) * 2021-02-10 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Tnf-alpha blocking agent for preventing, suppressing and/or delaying the onset of type 1 diabetes
EP4299076A4 (en) * 2021-02-26 2025-04-16 Biozipcode, Inc. NEW METHOD AND MEANS FOR THE TREATMENT, DIAGNOSIS AND DETECTION OF DIABETES AND COMPLICATIONS
CN117957251A (zh) * 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
KR20250031013A (ko) * 2023-08-23 2025-03-06 (주)셀트리온 TNFα 관련 질환을 치료하는 방법

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US6419927B1 (en) 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
AU560087B2 (en) 1981-09-08 1987-03-26 Rockefeller University, The Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4822776A (en) 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6309640B1 (en) 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JPS61100158A (ja) 1984-10-22 1986-05-19 Fukuarare Honpo:Kk 納豆付米菓の製造方法およびその製品
EP0212489B1 (en) 1985-08-16 1994-11-30 The Rockefeller University Anabolic activity modulator and uses thereof
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
GB8805792D0 (en) 1988-03-11 1988-04-13 Celltech Ltd Medicaments
DE3823804A1 (de) 1988-07-14 1990-01-18 Basf Ag Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
AU626572B2 (en) 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5360716A (en) 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
JPH02227095A (ja) 1988-10-24 1990-09-10 Otsuka Pharmaceut Co Ltd モノクローナル抗体
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5342613A (en) 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
PT92900A (pt) 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
US4936843A (en) 1989-02-16 1990-06-26 Ace Orthopedic Manufacturing Kirschner wire clamp and tensioner
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
CA2017025C (en) 1989-05-18 2008-07-22 David Wallach Tumor necrosis factor binding protein ii, its purification and antibodies thereto
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
DK0433900T3 (da) 1989-12-13 1996-01-29 Yeda Res & Dev Ekspression af rekombinant tumornekrosefaktor bindingsprotein I (TBP-I)
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
SG63617A1 (en) 1991-01-18 1999-03-30 Amgen Boulder Inc Methods for treating tumar necrosis factor mediated diseases
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE69233701T2 (de) 1991-03-18 2008-04-10 New York University Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
BR9206313A (pt) 1991-07-25 1995-04-11 Idec Pharma Corp Anticorpos recombinantes para terapia humana.
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0525570A3 (en) 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
NO178839C (no) 1991-11-25 1996-06-12 Ottestad Nils T Strömningsregulator for opprettholdelse av en stabil strömningsmengde av et fluidum
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DE69321909T2 (de) 1992-08-28 1999-04-01 Bayer Corp., Pittsburgh, Pa. Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
JP3616091B2 (ja) 1992-10-08 2005-02-02 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
AU682156B2 (en) 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
DK0614984T4 (da) 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
SE9302490D0 (sv) 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9403909D0 (en) 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
FR2728793A1 (fr) 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
JPH11127855A (ja) 1997-10-27 1999-05-18 Japan Energy Corp 組換え型抗ヒトＴＮＦ−αヒトモノクローナル抗体
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
AU2003225976A1 (en) 2002-03-26 2003-10-13 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN103254309B (zh) * 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
KR20080048505A (ko) * 2005-08-31 2008-06-02 센토코 인코포레이티드 증진된 작용자 기능을 지닌 항체 불변 영역을 생산하기위한 숙주 세포주
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
EP2964669B1 (en) * 2013-03-06 2018-09-12 Protalix Ltd. Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy

Also Published As

Publication number Publication date
MA43982A (fr) 2018-12-12
CA3012465A1 (en) 2017-08-10
EP3411504A2 (en) 2018-12-12
AU2017215317A1 (en) 2018-08-09
CN109072303A (zh) 2018-12-21
WO2017136524A2 (en) 2017-08-10
KR20180105711A (ko) 2018-09-28
EP3411504A4 (en) 2019-09-11
JP2019509988A (ja) 2019-04-11
US10465003B2 (en) 2019-11-05
US11124565B2 (en) 2021-09-21
MX2018009498A (es) 2019-05-06
US20170247444A1 (en) 2017-08-31
US20190092849A1 (en) 2019-03-28
US20190375836A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
BR112017002422A2 (pt) domínio de ligação a cd3
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112018067458A2 (pt) anticorpos para tigit
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
CO6700829A2 (es) Moduladores novedosos y métodos de uso
AR087715A1 (es) Anticuerpos anti pcsk9 y usos de los mismos
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
MX2019009377A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
EA201791813A1 (ru) Применение выделенных фракций мастиковой смолы для лечения нейропатии зрительного нерва
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2708 DE 29-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.